IntelliGenome, a Houston based diagnostics company, has signed a deal with Monterrey's CTR Scientific to distribute its CRISPR TB blood assay in Mexico.
In a pediatric TB clinic in southern Mexico, the standard diagnostic often comes down to a request a two-year-old cannot answer: produce sputum, the mucus coughed up from deep in the lungs, and do it on demand. For young children, for people living with HIV, and for patients whose TB sits outside the lungs in the lymph nodes, spine, or brain, that ask is frequently impossible, and the disease goes undiagnosed or is confirmed only after weeks of waiting and invasive sampling. The diagnostic gap is the problem a new partnership between Houston-based IntelliGenome and Monterrey's CTR Scientific says it wants to address in Mexico. The distance between a distribution agreement and a child actually getting a result, however, is wide, and depends on evidence the company has not yet published.
IntelliGenome announced on June 15, 2026 that it has signed an exclusive distribution deal with CTR Scientific, formally Control Técnico y Representaciones S.A. de C.V., for the CRISPR-TB Blood Test in Mexico. The assay, according to the company, detects fragments of Mycobacterium tuberculosis DNA circulating in the blood, a "cell-free DNA" approach that sidesteps the sputum requirement entirely. CTR Scientific, which the release describes as having a footprint across Mexican clinical and research laboratories, will handle logistics, regulatory support, and onboarding of public- and private-sector customers.
The clinical case for a blood-based TB test is not abstract. Mexico's national TB program has long struggled with underdiagnosis in children, in people living with HIV, and in patients with extrapulmonary disease, the category of infections that occur in the lymph nodes, bones, or central nervous system rather than the lungs. In those cases, bacteria rarely reach the airways in high enough concentrations to register in a sputum smear. Pediatric TB in particular is widely understood to be undercounted in Latin America, in part because young children simply cannot produce the sample the standard test requires. The IntelliGenome release frames CRISPR-TB explicitly as a tool for those populations.
What the release does not address is performance. The announcement does not disclose peer-reviewed sensitivity or specificity data, and the language used in the press release, including "potential," "future commercialization," and "supporting evaluation," is forward-looking rather than a statement of present clinical availability. The release also does not address whether IntelliGenome holds CE marking under Europe's in vitro diagnostic regulation or any equivalent independent performance validation in the patient groups, including children, HIV-positive adults, and extrapulmonary cases, that the test is most often marketed to reach.
That last point matters because "evaluation" in Mexico is not the same as clearance. Mexico's Federal Commission for Protection against Sanitary Risks, COFEPRIS, is the agency that ultimately decides whether a novel in vitro diagnostic can be sold and used in clinical care, and the June 15 announcement does not address where the assay stands in that process. The release does not disclose a regulatory submission to COFEPRIS, nor does it point to peer-reviewed clinical data that the agency would weigh in any review.
For now, the deal puts a name and a route to market behind a technology that has been largely absent from the Mexican conversation. Whether it shortens the diagnostic odyssey for the children and HIV-positive adults the press release invokes will depend on evidence the company has not yet put in front of clinicians, regulators, or peer reviewers, and on whether Mexico's evaluation process demands that evidence before any patient is tested.